FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
The approval of Apidra for pediatric use is based upon FDA review of a 26-week, phase III, open-label, active control study of Apidra in comparison with insulin lispro, in 572 children and adolescents with type …
Research shows aerobic exercise combined with resistance training…
Patients with diabetes who participate in a program combining aerobic and high-force eccentric resistance exercise demonstrate improvements in glucose control, physical performance, and body fat composition, …
Possible Case: VIBE
FDA Issues Class I Recall
Well-known drug (AAT) could overcome obstacles to islet transplantation
Researchers from Ben-Gurion University of the Negev in Beer-Sheva, Israel have demonstrated that treating diabetic animals with alpha-1-antitrypsin following an islet transplantation procedure eliminates the …
Vibe Technologies Vibrational Integrated Bio-photonic Energizer Machine Multi-Frequency Field Generator
Class I recall because of unsupported claims.
Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1):
Q3 2008: EUR 1.47, up 5.0% –> up 15.6% in U.S. dollars(2)
First 9 months of 2008: EUR 4.24, up 3.4% –> up 17.5% in U.S. dollars(2)
BRIDGEWATER, N.J., October 31, 2008 /PRNewswire-FirstCall/ — In order to give a representation…
Type-1 Diabetes Not So Much Bad Genes as Good Genes Behaving Badly, Stanford Research Shows
Investigators combing the genome in the hope of finding genetic variants responsible for triggering early-onset diabetes may be looking in the wrong place, new research at the Stanford University School of …
GSK Believes There Is No Liver Safety Issue With Avandia; Responds to Public Citizen Petition
PHILADELPHIA, October 30, 2008 /PRNewswire-FirstCall/ — GlaxoSmithKline today issued the following response to a petition filed by Public Citizen to the U.S. Food and Drug Administration (FDA) on Avandia (rosiglitazone maleate), a highly effective…
Schering-Plough to Appeal Jury Decision in Missouri Reimbursement Case
ST. LOUIS, October 30, 2008 /PRNewswire-FirstCall/ — Schering-Plough Corporation said today that it strongly believes that the decision reached by a jury in Missouri related to reimbursement by Missouri’s Medicaid program of certain products sold…
Sanofi best-sellers help lift net profit in 3Q
French pharmaceutical giant Sanofi-Aventis said Friday that higher sales of blood thinners Lovenox and Plavix and diabetes treament Lantus helped lift net profit by 1.9 percent in the third quarter.
Paris-based Sanofi-Aventis said its adjusted net profit was 1.89 billion euros ($2.46 billion) in the period. The figure is adjusted to exclude the acquisition and restructuring costs related to the 2004 acquisition of Aventis by Sanofi-Synthelabo.
The world’s third-largest pharmaceutical company by prescription sales also hiked its growth target for earnings per share this year to 9 percent on an adjusted basis and excluding foreign exchange impact, up from its July guidance of an 8 percent increase.
keep looking »